Discovery of 1-(Azetidin-3-ylmethyl)-1 H -benzo[ d ]imidazole Derivatives as Efficient GSTP1 Inhibitors for Gastric Cancer Treatment via Warhead Removal Strategy
Authors:
- 3 March 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5622-5647
Abstract
Gastric cancer is commonly diagnosed at advanced stages and frequently develops multidrug resistance (MDR). Clinical evidence highlights the overexpression of glutathione S-transferase pi 1 (GSTP1) in gastric cancer, which is closely associated with tumor progression and the development of MDR. However, highly potent and selective GSTP1 inhibitors remain scarce. Guided by our previously reported covalent DNA-encoded library (DEL) hit, a series of warhead-removed 1-(azetidin-3-ylmethyl)-1H-benzo[d]imidazole derivatives were obtained as noncovalent GSTP1 inhibitors. The most potent compound, 16n, inhibited GSTP1 enzymatic activity with an IC50 value of 0.79 ± 0.05 μM and demonstrated improved isoform selectivity. In human gastric cancer cells (AGS, HGC27, and NUGC-3), 16n dose-dependently suppressed proliferation and increased intracellular reactive oxygen species levels while decreasing glutathione levels. Importantly, 16n exhibited favorable systemic exposure and achieved 58% tumor growth inhibition with good tolerability in HGC27 xenograft mouse models. Collectively, 16n represents a promising noncovalent GSTP1 inhibitor for the treatment of gastric cancer.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2023YFC3603303)
- Science and Technology Commission of Shanghai Municipality (21TQ016)
- Science and Technology Commission of Shanghai Municipality (YDZX20233100004032)
- Ministry of Science and Technology of the People's Republic of China (22337004)
- Ministry of Science and Technology of the People's Republic of China (U24A20524)
- Chinese Academy of Sciences (XDB0830000)
This publication has 64 references indexed in Scilit:
- HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancerCell Metabolism, 2025
- Advancements, challenges, and future frontiers in covalent inhibitors and covalent drugs: A reviewEuropean Journal of Medicinal Chemistry Reports, 2024
- Deciphering drug resistance in gastric cancer: Potential mechanisms and future perspectivesBiomedicine & Pharmacotherapy, 2024
- Targeting GSTP1 as Therapeutic Strategy against Lung Adenocarcinoma Stemness and Resistance to Tyrosine Kinase InhibitorsAdvanced Science, 2023
- Designed switch from covalent to non-covalent inhibitors of carboxylesterase Notum activityEuropean Journal of Medicinal Chemistry, 2023
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Recent Advances in Selective and Irreversible Covalent Ligand Development and ValidationCell Chemical Biology, 2019
- Identification of human, rat and mouse hydrolyzing enzymes bioconverting amino acid ester prodrug of ketoprofenBioorganic Chemistry, 2018
- Glutathione transferase P1‐1 as an arsenic drug‐sequestering enzymeProtein Science, 2016
- The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancerFree Radical Biology and Medicine, 2011